EMA starts rolling review of COVID-19 vaccine Vidprevtyn (Sanofi Pasteur), EMA (published 20th July 2021)

The decision to review this vaccine is based on preliminary results from laboratory and early clinical studies in adults suggesting it effectively triggers antibody production. It is a protein-based vaccine that contains a laboratory-grown version of the spike protein.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news